SCHEMBL7705298

SCHEMBL7705298

O=C1NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)CC1=S

nearest known ligand 0.55

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CDA P32320 9/20 0.54
▸ SLC28A1 O00337 1/20 0.42
▸ SLC28A2 O43868 1/20 0.42
▸ SLC29A1 Q99808 1/20 0.42
▸ SLC28A3 Q9HAS3 1/20 0.42
▸ MAPT P10636 1/20 0.40
▸ PYGM P11217 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29047907 0.86 CDA (0.55) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL10859054 0.83 CDA (0.52) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL29180738 0.81 CDA (0.54) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL7452161 0.80 CDA (0.49) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL7452167 0.80 CDA (0.49) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL15010376 0.78 CDA (0.54) CDASLC28A1SLC28A2SLC29A1SLC28A3
SCHEMBL10709774 0.77 P2RY2 (0.56) —
SCHEMBL6026652 0.77 TK1 (0.43) —
SCHEMBL5982761 0.77 TK1 (0.43) —
SCHEMBL15010708 0.76 CDA (0.52) CDASLC28A1SLC28A2SLC29A1SLC28A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023217209-A1 DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF 澳门科技大学 2023-11-16 — — WO claimed
CN-114875027-A Double-stranded RNA molecule and medical application thereof 澳门科技大学 2022-08-09 — — CN claimed
CN-117642421-A Engineered immune cells specifically targeting mesothelin and uses thereof 武田药品工业株式会社 2024-03-01 — — CN disclosed
CN-115927301-B RNAi-based spodoptera frugiperda control method 西北农林科技大学 2024-02-23 — — CN disclosed
WO-2024008192-A2 MODIFIED SELF-REPLICATING MRNA 嘉晨西海(杭州)生物技术有限公司 2024-01-11 — — WO disclosed
CN-117377756-A Engineered immune cell therapies 菲克特生物科学股份有限公司 2024-01-09 — — CN disclosed
WO-2023217209-A1 DOUBLE-STRANDED RNA MOLECULE AND PHARMACEUTICAL USE THEREOF 澳门科技大学 2023-11-16 — — WO disclosed
CN-115927301-A Rnai-based Spodoptera frugiperda control method 西北农林科技大学 2023-04-07 — — CN disclosed
CN-115701285-A Mesenchymal stem cell therapy 菲克特生物科学股份有限公司 2023-02-07 — — CN disclosed
CN-115052986-A Compositions comprising nucleases and uses thereof 阿伯生物技术公司 2022-09-13 — — CN disclosed
CN-114875027-A Double-stranded RNA molecule and medical application thereof 澳门科技大学 2022-08-09 — — CN disclosed
CN-112805386-A Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail 埃泽瑞斯公司 2021-05-14 — — CN disclosed
CN-111819185-A Compositions comprising cyclic polyribonucleotides and uses thereof 旗舰创业创新第六有限责任公司 2020-10-23 — — CN disclosed
CN-111744019-A Mannose-based mRNA (messenger ribonucleic acid) targeted delivery system and application thereof 深圳市瑞吉生物科技有限公司 2020-10-09 — — CN disclosed
CN-110914433-A Nucleic acids encoding CRISPR-associated proteins and uses thereof 库尔维科公司 2020-03-24 — — CN disclosed
EP-2833921-A2 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS Moderna Therapeutics, Inc. (US) 2015-02-11 — — EP disclosed
WO-2013151668-A2 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS modeRNA Therapeutics (US) 2013-10-10 — — WO disclosed
US-20020182626-A1 Episomal non-transforming nucleic acid elements in functional genomic and antigenic applications LARGE SCALE BIOLOGY CORPORATION 2002-12-05 — — US disclosed
WO-2002075306-A1 EPISOMAL NON-TRANSFORMING NUCLEIC ACID ELEMENTS IN FUNCTIONAL GENOMIC AND ANTIGENIC APPLICATIONS LARGE SCALE BIOLOGY CORPORATION (US) 2002-09-26 — — WO disclosed
US-4749647-A Polymerization-induced separation assay using recognition pairs GENETIC SYSTEMS CORPORATION (US) 1988-06-07 — — US disclosed
Send feedback